Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.48 USD
-0.01 (-0.67%)
Updated May 16, 2024 04:00 PM ET
After-Market: $1.46 -0.02 (-1.35%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ITRM 1.48 -0.01(-0.67%)
Will ITRM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITRM
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
Other News for ITRM
Analysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), Iterum Therapeutics (ITRM) and Cara Therapeutics (CARA)
Buy Rating Affirmed for Iterum Therapeutics on Strong Market Potential and Financial Stability
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024
Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript